Krumme D - Search Results

1

NMR studies of the interaction of tryparedoxin with redox-inactive substrate homologues.

Krumme D, Budde H, Hecht HJ, Menge U, Ohlenschläger O, Ross A, Wissing J, Wray V, Flohé L. Krumme D, et al. Biochemistry. 2003 Dec 23;42(50):14720-8. doi: 10.1021/bi030112d. Biochemistry. 2003. PMID: 14674746

2

Tryparedoxin peroxidase of Leishmania donovani: molecular cloning, heterologous expression, specificity, and catalytic mechanism.

Flohé L, Budde H, Bruns K, Castro H, Clos J, Hofmann B, Kansal-Kalavar S, Krumme D, Menge U, Plank-Schumacher K, Sztajer H, Wissing J, Wylegalla C, Hecht HJ. Flohé L, et al. Among authors: krumme d. Arch Biochem Biophys. 2002 Jan 15;397(2):324-35. doi: 10.1006/abbi.2001.2688. Arch Biochem Biophys. 2002. PMID: 11795890

3

Optimised fermentation strategy for 13C/15N recombinant protein labelling in Escherichia coli for NMR-structure analysis.

Ross A, Kessler W, Krumme D, Menge U, Wissing J, van den Heuvel J, Flohé L. Ross A, et al. Among authors: krumme d. J Biotechnol. 2004 Feb 19;108(1):31-9. doi: 10.1016/j.jbiotec.2003.10.014. J Biotechnol. 2004. PMID: 14741767

4

1H, 15N and 13C resonance assignments and secondary structure of tryparedoxin-I from Crithidia fasciculata.

Krumme D, Hecht HJ, Menge U, Ross A, Wray V, Flohé L. Krumme D, et al. J Biomol NMR. 2002 Apr;22(4):375-6. doi: 10.1023/a:1014999207047. J Biomol NMR. 2002. PMID: 12018487 No abstract available.

5

Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.

Krumme D, Tschesche H. Krumme D, et al. Bioorg Med Chem Lett. 2002 Mar 25;12(6):933-6. doi: 10.1016/s0960-894x(02)00052-5. Bioorg Med Chem Lett. 2002. PMID: 11958997

6

Hydroxamate derivatives of substrate-analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases.

Krumme D, Wenzel H, Tschesche H. Krumme D, et al. FEBS Lett. 1998 Oct 2;436(2):209-12. doi: 10.1016/s0014-5793(98)01128-4. FEBS Lett. 1998. PMID: 9781680 Free article.

7

Ten years' experience with cyclosporine monotherapy after renal transplantation.

Hillebrand G, Schneeberger H, Schleibner S, Krumme D, Hillebrand C, Burkhardt K, Hacker H, Illner WD, Land W. Hillebrand G, et al. Among authors: krumme d. Transplant Proc. 1993 Feb;25(1 Pt 1):513-4. Transplant Proc. 1993. PMID: 8438395 No abstract available.

8

Cyclosporine monotherapy--an ideal long-term immunosuppression?

Schleibner S, Schneeberger H, Hillebrand G, Illner WD, Krumme D, Roed M, Land W. Schleibner S, et al. Among authors: krumme d. Transplant Proc. 1990 Aug;22(4):1695-6. Transplant Proc. 1990. PMID: 2389435 No abstract available.

9

Is withdrawal of steroids hazardous to cadaveric renal transplants under treatment with cyclosporine?

Hillebrand G, Krumme D, Schleibner S, Land W, Gurland HJ. Hillebrand G, et al. Among authors: krumme d. Transplant Proc. 1988 Jun;20(3 Suppl 3):126-9. Transplant Proc. 1988. PMID: 3291225 No abstract available.

10

The analysis of space use patterns.

Ford RG, Krumme DW. Ford RG, et al. Among authors: krumme dw. J Theor Biol. 1979 Jan 21;76(2):125-55. doi: 10.1016/0022-5193(79)90366-7. J Theor Biol. 1979. PMID: 431092 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters